Geneva Capital Management LLC Reduces Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Geneva Capital Management LLC reduced its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 2.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 117,718 shares of the medical device company’s stock after selling 3,049 shares during the period. Geneva Capital Management LLC’s holdings in Cooper Companies were worth $12,989,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in COO. Innealta Capital LLC bought a new position in shares of Cooper Companies during the 2nd quarter valued at approximately $25,000. Ashton Thomas Securities LLC bought a new stake in Cooper Companies during the third quarter valued at about $25,000. Covestor Ltd boosted its stake in shares of Cooper Companies by 305.9% in the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after acquiring an additional 208 shares during the period. Crewe Advisors LLC grew its position in shares of Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after purchasing an additional 252 shares in the last quarter. Finally, Tortoise Investment Management LLC raised its stake in Cooper Companies by 75.4% during the 2nd quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 169 shares during the period. 24.39% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cooper Companies

In other news, COO Daniel G. Mcbride sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the sale, the chief operating officer now owns 44,696 shares of the company’s stock, valued at approximately $4,714,534.08. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Brian G. Andrews sold 24,788 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the completion of the sale, the chief financial officer now owns 6,614 shares of the company’s stock, valued at $700,422.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Daniel G. Mcbride sold 114,992 shares of Cooper Companies stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the transaction, the chief operating officer now directly owns 44,696 shares in the company, valued at $4,714,534.08. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 256,373 shares of company stock valued at $27,637,427 in the last three months. Company insiders own 2.00% of the company’s stock.

Cooper Companies Stock Down 1.5 %

Shares of NASDAQ COO opened at $102.00 on Wednesday. The company has a market cap of $20.31 billion, a P/E ratio of 56.82, a PEG ratio of 2.23 and a beta of 0.99. The firm has a 50-day simple moving average of $107.18 and a two-hundred day simple moving average of $97.82. The Cooper Companies, Inc. has a 1 year low of $81.99 and a 1 year high of $112.38. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.99 and a quick ratio of 1.18.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.91 by $0.05. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $997.30 million. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. Cooper Companies’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.84 EPS. Research analysts anticipate that The Cooper Companies, Inc. will post 3.65 earnings per share for the current year.

Wall Street Analyst Weigh In

COO has been the subject of a number of research analyst reports. Piper Sandler increased their price objective on shares of Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. StockNews.com upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a report on Friday, November 8th. Wells Fargo & Company increased their price objective on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $115.00 target price (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Finally, Robert W. Baird increased their price target on Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Cooper Companies presently has a consensus rating of “Moderate Buy” and an average price target of $117.00.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.